Agomelatine targets a range of major depressive disorder symptoms.
Servier, and US licensee Novartis AG, are developing the oral melatonin MT1 and MT2 agonist and 5-HT2B and 5-HT2C antagonist agomelatine as a once-daily treatment for major depressive disorder (MDD) and its symptoms, particularly anxiety, and sleep and circadian disturbances. Phase III trials have been completed and a registration dossier has been submitted to the EMEA in Western Europe.
Dubocovich
Margarita L
ML
Department of Molecular Pharmacology and Biological Chemistry, The Feinberg School of Medicine, Center for Drug Discovery and Chemical Biology, Northwestern University, Chicago, IL 60611, USA.
D000081:Acetamides / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D000928:Antidepressive Agents / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D001007:Anxiety / Q000523:psychology; D002940:Circadian Rhythm / Q000502:physiology; D002986:Clinical Trials as Topic; D000075202:Contraindications; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004353:Drug Evaluation, Preclinical; D006801:Humans; D044094:Receptors, Melatonin / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D012890:Sleep / Q000187:drug effects; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D013329:Structure-Activity Relationship; D009281:Naphthalenes
D000081:Acetamides; D000928:Antidepressive Agents; D044094:Receptors, Melatonin; D011985:Receptors, Serotonin; C084711:agomelatine; D009281:Naphthalenes